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CHANGING THE WAY WE THINK ABOUT IRRITABLE BOWEL SYNDROME
Roger Coron, MD,1 Herve Boucard, MD,2 and Zamir Brelvi, MD 2
Irritable bowel syndrome has long been considered a functional
gastrointestinal disorder. However, recent studies have suggested
possible organic causes that can explain the multitude of
symptoms in IBS.

Brief History
The irritable bowel syndrome has been thought of as a functional
gastrointestinal disorder for many years. As long as three thousand
years ago, Hippocrates described a triad of symptoms consisting
of abdominal discomfort, irregular bowel movements and
bloating. In 1817, William Powell reported a case with similar
symptoms as Hippocrates. In 1849, Cumming described a
syndrome of irregular bowel habits consisting of alternating
diarrhea and constipation.1 In 1928, Bockus and his colleagues
described the syndrome as “neurogenic mucous colitis.”2 Bockus
determined that this disease can only be diagnosed by exclusion
which was the belief until the 1970’s.

Epidemiology
Today IBS is one of the most common diagnosed medical
problem affecting an estimated 4-35% of the population
worldwide, with a prevalence of 9-22% in the United States.1,3-5
Approximately 12% of office visits in the United States are due to
IBS along with approximately 28% of gastroenterology referrals.1,68
It is the 7th most common outpatient diagnosis. Irritable bowel
syndrome is the second most common cause for absenteeism,
trailing only the common cold. Disability rates are equal to or
more severe than organic GI diseases. The prevalence rate is 2-3
times higher in women.1 This appears to be the case worldwide
except in India and Sri Lanka where there is no known gender
differences.9 Hispanics and Asians are less likely to have IBS. There
have been conflicting studies on the prevalence differences for
Caucasians versus African Americans. The onset usually is in the
late teenage years and twenties. The prevalence peaks in the 3rd
and 4th decades and begins to decline in the 6th and 7th
decades.1,3,4 After diagnosis, up to 75% of patients will remain
symptomatic after 5 years.10

Economics
IBS patients miss three times as many work days as the average
person. In the United States, the disease accounts for 3.5 million
office visits, 2.2 million prescriptions and 35,000 hospitalizations
per year. Patients with IBS use more medical resources than the
non-IBS patient. These include physician visits, tests, unnecessary
surgeries and medications. It is currently estimated that IBS costs
the United States between 15-30 billion dollars per year.11-13 This
includes both direct medical costs as well as indirect costs.

Extraintestinal symptoms
Patients with IBS undergo more appendectomies and hysterectomies than non-IBS patients. The most common extraintestinal
manifestations include genito-urinary symptoms such as
dysmenorrhea, dyspareunia, impotence, urinary frequency, as well
as feelings of incomplete bladder emptying. IBS also appears to
affect the perception of sexual function. Eighty-three percent of
IBS patients compared to 16% of non-IBS patients report
impaired sexual functioning.

Diagnosis
The diagnosis of irritable bowel syndrome was originally made
using the Manning criteria: pain eased with defecation, pain
associated with change in frequency of bowel movements, pain
associated with change in consistency of bowel movements,
abdominal distention, tenesmus, and mucous in the stool.14 In
1992, the Rome criteria for the diagnosis of irritable bowel
syndrome was published. In 2000, the Rome II criteria was
published (See Table 1)14 In a study of 98 patients, confirmed to
have IBS using a clinicians diagnosis as the gold standard, it was
found that the Rome I criteria in the absence of red flags to be
65% sensitive, 100% specific and 100% positive predictive value.
The cornerstone of the Rome Criteria is abdominal pain. Without
abdominal pain, IBS can not be the diagnosis.1

Table 1. The ROME I Criteria for the diagnosis of IBS was developed in 1992
ROME I Criteria:

Rome 2 Criteria

Red Flags

Presence for at least 12 weeks (not necessarily consecutive)
in the preceding 12 months of abdominal discomfort or pain
that cannot be explained by structural or biochemical
abnormalities and at least two of the following

2 or more of the following,
at least 25% of occasions
or days:

1. Documented weight loss
2. Nocturnal Symptoms

1. Pain relieved with defecation

1. Altered stool frequency

3. Blood mixed in the stool

2. Change in the frequency of bowel movements

2. Altered stool forms

4. Recent antibiotic use

3. Change in the form of the stool

3. Altered stool passage

5. Family history of colon cancer

4. Bloating or feeling
abdominal distention

6. Relevant abnormalities
on physical exam (2)

1
2
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Gender and Hormones
Hormones appear to play a role in IBS. The symptoms appear
to be worse in women during menstruation.15 Women on
hormone replacement therapy tend to be more symptomatic
than women not on therapy.16 One study found that men with
IBS are more likely to have lower testosterone and luteinizing
hormone than unaffected men.17 Other studies have found that
men with IBS have more nurturing traits and reduction in the
male-trait score.18,19

within one week compared to just 11% in placebo-treated
patients. Of the patients who bacterial eradication was considered
complete, 75 percent achieved normalization of global
symptoms.26 Another study proved that metronidazole is superior
to placebo in alleviating symptoms in IBS.27 This is further
evidence of bacterial overgrowth as the potential etiology in at
least some IBS patients.

A history of abuse predisposes patients to IBS. In addition to
having a history of abuse of varying types; emotional, sexual, or
physical and/or a history of stressful life events, social stress or
anxiety and having a maladaptive coping style, affect the severity
and clinical course of IBS.20 There is a strong association between
IBS and having a concurrent psychological disturbance. Various
studies have demonstrated a 40-90 percent association rate with
IBS. Psychological disorders associated with IBS include
personality disorders, psychological distress, altered health beliefs
and coping styles.20

In recent years, studies have shown that a high percentage of people
with infectious gastroenteritis develop IBS. This was demonstrated
in two control studies. The first study followed 318 subjects with
gastroenteritis and compared them to a population database of
584,308 controls for one year to see if a diagnosis of IBS was made.
They found that 4% of the post-infectious patients had developed
IBS within 12 months compared to 0.3% of the general
population.28 A second study29 followed post-infectious gastroenteritis subjects and controls for 6 months and found that 17% had
developed IBS compared to only 1.9% of the controls. The odds
ratio was 10 (95% confidence interval, 3-31). This study used the
Rome II criteria for diagnosis of IBS.30 Overall, the incidence of
post-infectious onset IBS has been shown to be between 4-30%.31

Infection

Inflammation

Researchers have suggested that IBS can be explained by bacterial
overgrowth in the small intestines. The theory stems from the
finding that regardless of the predominant symptom of IBS, 92%
of the patients complain of abdominal bloating.21 The bloating is
usually postprandial. Numerous imaging studies show increased
intestinal gas in IBS patients. Total hydrogen gas excretion and
the maximal rate of gas excretion following lactulose ingestion
was higher in IBS patients.22 The gases produced are hydrogen
and methane which demonstrates that this abnormal gas
production following lactulose intake in IBS patients cannot be
explained by simply a disaccharide intolerance.

Several studies have shown the presence of increased inflammatory
cell levels in patients with IBS.20 These findings include increased
mast cells in the muscularis externa of the colon and ileum,
increased cellularity of the colonic and ileal mucosa, lymphocytic
infiltrates in the myenteric plexus and increased nitrous oxide
synthetase.32-37 The findings of inflammation occur usually within
three months of infectious gastroenteritis. During this time
period, IBS patients have a higher lymphocyte count in the rectal
mucosa. The count is not high enough to meet the criteria for
lymphocytic colitis.38 A small study of patients with severe IBS
have shown that on full thickness biopsy, a low grade ganglionitis
existed. Two of the ten IBS patients with the low grade
ganglionitis had post-infectious IBS.39 There is also evidence that
low grade inflammation of the small intestine such as the
inflammation following Campylobacter infection could cause bile
acid malabsorption.38 This in turn could cause the symptoms of
post-infectious IBS.

Psychological Factor and Abuse

Normally, it is uncommon for bacteria to grow in the proximal
small intestine. It has been theorized that there is a proximal
spread of bacteria along the small intestines. New bacterial growth
in the proximal small intestine may be the cause of the increased
gas production in IBS patients.23 Nucera et al24 found that out of
200 patients with IBS, 75 percent had abnormal lactulose-glucose
breath tests. This is consistent with bacterial overgrowth of the
small intestine.
Another study found that 78% of IBS patients had an abnormal
breath test. This suggested that a small intestine bacterial
overgrowth may be present. The study consisted of 202 IBS
patients who had met the Rome I Criteria. They were treated with
antibiotics with successful eradication of the bacteria being
measured by a normal breath test. After eradication, half of the
patients no longer met the Rome I Criteria.25 This study was
followed with a double-blind randomized control trial. This
follow-up study consisted of 111 patients with IBS. Thirty-seven
percent of those with IBS had normalization of global symptoms

Enteric nervous system
One of the earliest studies to show that the nervous system played
an important role in IBS involved the difference in perception of
pain in patients with IBS compared to controls. Ritchie40 found
that patients with IBS experienced rectal pain when a balloon was
inflated in the rectum at lower volumes than non-IBS patients. In
this study, fewer than 10% of non-IBS subjects reported pain at a
distending volume of about 60 ml compared to greater than 50%
of IBS patients reporting pain at the same distending volume.
The enteric nervous system (ENS) is a complex system that rivals
the spinal cord and brain in the number of nerves and neurotransmitters involved. It can work both in conjunction with the CNS as
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well as on its own as demonstrated in pig intestines in vitro.41
Intrinsic primary afferent neurons(IPAN) are analogous to dorsal
root ganglia of the CNS. They are the peripheral sensors that feed
information to the ENS in order to allow autonomous regulation of
the gut by the ENS. Drugs that activate IPANs stimulate diarrhea
and drugs that inhibit their action cause constipation. One clinical
trial used 5-Hydroxyindalpin to stimulate the IPANs and the result
was diarrhea.42 It has been theorized, however, that a drug that targets
the distal terminal of IPANs may lead to better control of gut
motility.41 When stimulated by 5HT-4, IPANs cause the release of
acetylcholine and calcitonin g related peptide.41 These neurotransmitters induce gut motility. 5HT-4 also causes the increase release of
5HT-4 at neuromuscular junctions and nerve-nerve synapses in the
myenteric plexus.43-45 The combination of these factors is the reason
that Tegaserod, a 5HT-4 receptor agonist, stimulates gut motility.
Tegaserod has been shown to provide relief of IBS-c (constipation
type) over placebo in several trials.41 5HT-3 is the signal used by
the CNS to interpret the intestinal tract environment. Like 5HT-4,
5HT-3 is part of the prokinetic pathway. Antagonizing 5HT-3 is
useful in the treatment of hypermotility states such as IBS-D
(diarrhea type). Alosetron and Cilansetron, 5HT-3 antagonists, have
been effective in the treatment of IBS-D.46-48

Celiac Disease
Celiac disease and irritable bowel syndrome share many common
gastrointestinal symptoms. It was found that patients with
irritable bowel syndrome as diagnosed by ROME II criteria have
a higher association with also having celiac disease as compared to
normal controls. One study tested for the presence of celiac disease
by the presence of serum IgA antigliadin, IgG antigliadin, and
endomysial antibodies in 300 patients diagnosed with IBS.
Positive antibody tests were followed by biopsy for confirmation
of the diagnosis. The results were compared to 300 patients who
did not carry the diagnosis of IBS. They found that 14 patients
with IBS also had celiac disease compared to just 2 of the nonIBS controls (p=0.004, odds ratio = 7.0 [95% CI 1.7-28]).
According to this study, it may be prudent to refer patients with
IBS for Celiac disease testing.49
Another smaller study comparing 34 subjects with dyspepsia, 50
subjects with IBS, and 78 asymptomatic healthy controls did not
show a statistically significant difference in the association with
celiac disease.50 However, in this study celiac disease was diagnosed
solely by serology. Whether there is an actual association between
the diseases or merely celiac patients falsely being labeled with
IBS remains to be seen. Future studies should look into the results
of treating the celiac disease to see if the IBS symptoms remain.

Diagnosis
Until recently, the diagnosis of IBS was a diagnosis of exclusion
which required a lengthy battery of tests. With the advent of the
Rome criteria, physicians have been able to make the diagnosis of
IBS on the basis of symptoms in the absence of red flags. Several
studies examined the pre-test probability and prevalence of
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organic disease in patients with IBS. Using flexible sigmoidoscopy,
colonoscopy, and barium enema, between 0-1.3% of patients were
found to have organic disease. Other studies using abdominal
ultrasonography and rectal biopsy failed to identify organic disease
in IBS patients. Laboratory studies such as a complete blood
count, chemistry panel and fecal occult blood testing similarly
found organic disease in only 0 to 1.3% of IBS patients. TSH was
abnormal in 0.6 to 6% of patients. Several studies have shown
that IBS patients have abnormal breath tests for lactose
intolerance in 22-26% of cases. However, one study found the
presence of an abnormal breath test in 78% of IBS patients.13 In
addition, Celiac disease was found to be more prevalent in IBS
patients, 5% compared to 1% of the general population.49,50
The alarms or red flags (see Table 1)14 used in the Rome criteria
such as hematochezia, anemia, weight loss, chronic severe diarrhea
and family history of colon cancer, all lead to a high pre-test
probability of organic disease and therefore justify initiating a
targeted work-up. The Rome I criteria was found to be 65%
sensitive, 100 % specific with a 100% predictive value for IBS.1

Treatment
The etiology of IBS is complex with overlapping etiologies
contributing to the symptoms. (See Figure 1) It has been proposed
that small bowel bacterial overgrowth, post-infectious states,
inflammatory states as well as psychological factors, all contribute
to the vast symptoms of IBS. For this reason, the treatment must
be tailored to each IBS patient. Patients with predominant
psychological etiology may do well with antidepressants and
behavioral therapy. Several studies have looked into treating
patients with antibiotics when bacterial overgrowth is the
suspected etiology. Other therapies are used to control symptoms
such as antispasmodics, bulking agents, and serotonin receptor
agonists and antagonists.

Antispasmodics
There are two antispasmodics available in the United States,
dicyclomine and hyoscyamine. These drugs are thought to work
by decreasing the spontaneous activity of the intestinal smooth
muscles. Atropine-like adverse effects often lead to intolerance
and the relaxation of the smooth muscle can worsen constipation.
Currently there is only a grade B recommendation for the use of
anti-spasmodic agents for IBS management.20 Five smooth muscle
relaxants were found to have greater efficacy than placebo. These
include cimetropium bromide, pinaverium bromide, octylonium
bromide, trimebutine, and mebeverine.51

Bulking agents
Several bulking agents have been studied including wheat, bran,
corn, fiber, calcium, polycarbophil, ispaghula husk and psyllium.
Bulking agents were effective in improving stool bulk and stool
frequency but they were not found to be more effective than
placebo. Adverse effects of bloating and abdominal discomfort
were worsened by those agents.20
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Figure 1: Diagram demonstrating the proposed overlapping etiologies
of IBS.

Figure 2: Algorithm for evaluation and treatment of IBS

Anti-diarrheal agents

though the magnitude of the improvements were different across
the trials. Alosetron has a grade A recommendation by the ACG
for IBS with diarrhea. The most commonly reported adverse effect
is constipation occurring in 22-39% of patients vs 3-14%
controls. Unfortunately, ischemic colitis is unpredictable.
Physicians are advised to adhere the FDA guideline of using
Alosetron for “women with severe, diarrhea-predominant IBS who
failed to respond to conventional IBS therapy” in view of the
potentially serious adverse effects.46-48

Diarrhea can be controlled with many over the counter agents
such as Loperamide which includes Immodium and Kaopectate
II among others. This agent works by slowing gut transit and up
regulating water and electrolyte absorption.52 Prescription Lomotil
can be used if the over the counter agents fail to provide relief.

Serotonin receptor agonist (5HT4)
Serotonin receptor activation stimulates peristalsis thereby
increasing intestinal and colonic transit time and also reduces
visceral sensitivity. Tegaserod is the only 5HT4 currently available.
Several well-designed, randomized, controlled trials using the
ROME criteria for diagnosis have demonstrated significant
improvement of constipation symptoms. The recommended
dosage is 6mg twice daily and the trials duration extended over
12 weeks. Significant reduction of bloating, abdominal discomfort
and improvement of bowel-habit satisfaction were reported but
the magnitude of these improvements were not consistent among
those trials. This is likely secondary to different methodology used
to evaluate the symptoms. 9-10% of patients reported diarrhea as
the most frequent adverse effects compared to 4-5% in the
placebo group.41 Another recent study looking at the efficacy of
Tegaserod for repeated therapy using 2660 patients found that
Tegaserod was superior to placebo in both initial use and repeated
therapy.53 It should be kept in mind that the FDA approved
regimen is only for short duration in females whose primary
symptom is constipation. The role of Tegaserod is not clearly
defined in patients with alternating constipation with diarrhea.
No recommendation exists for males.

Serotonin receptor antagonist 5HT3
5HT3 antagonism slows colonic transit and improves discomfort.
Alosetron is the first FDA-approved 5HT3 receptor antagonist
for the treatment of IBS with diarrhea. Because of reported cases
of ischemic colitis, its use was stopped in November 2000. The
FDA allowed the marketing of the drug again in June 2002 at the
dose of 1mg twice daily. Four trials resulted in statistically
significant improvement in abdominal pain and fecal urgency

Behavioral and psychotropic therapy
Because of the frequent findings of psychological disorders in IBS,
especially depression and anxiety disorders, behavioral therapies
have been tried for treatment. There have been at least 16
randomized controlled trials. Presence of a psychological disorder
was found in 80% of patients. Unfortunately, these trials
contained flaws in the methodology. Behavioral therapy seems to
improve both the IBS symptoms and the psychological manifestations although the evidence fails to be unequivocal. Currently,
only behavioral therapy has Grade A recommendation for the
treatment of IBS.20
The use of antidepressants has been helpful in some patients.
Those with abdominal pain, bloating and diarrhea seem to be
most susceptible to the benefits of tricyclic antidepressants.54 The
mechanism of action is two-fold. First, they appear to effect
motility and visceral sensitivity as well as central pain perception.55
They also have anticholinergic effects which can help with
diarrhea. More recent studies have found SSRIs to be somewhat
helpful in alleviating symptoms and improving mood.20

Hypnotherapy
Several studies have evaluated the benefit of hypnotherapy in
reducing symptoms of IBS in both the short and long-term. One
study consisted of IBS patients receiving weekly 1-hour session of
gut-directed hypnotherapy for a total of 12 weeks. They found
that the patients improved in the long-term follow-ups.56 Another
study followed 204 patients using questionnaires for 6 years. They
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found that initially 71% of the patients had symptom
improvement. After 5 years, only 19% of the patients who initially
responded had regressed. Measures of quality of life, anxiety, and
depression all were statistically significantly improved.57

Future therapy
There is overwhelming evidence that small bowel bacterial
overgrowth is prevalent in a much higher percentage of patients
with IBS compared to the healthy population. There is current
research looking into an algorithm for treating IBS according to
this data. The algorithm calls for a lactulose breath test at the time
of initial patient presentation. If the breath test is positive,
treatment with Cipro/Flagyl have been successful in eradicating
bacterial overgrowth, resulting in a negative breath test.25,26
Following bacterial eradication, patients can then be started on
traditional therapy for IBS up to and including the 5HTa agonists
and antagonists. We are currently studying the efficacy of Xifaxan
400 mg TID and comparing it to Cipro or Flagyl for use in
bacterial eradication in the small bowel. It is our opinion that
small bowel bacterial overgrowth is not the only etiology of IBS
but one of many triggers.
■

References
1. Lacy BE, Lee RD. Irritable bowel syndrome: a syndrome in evolution. Journal of
Clinical Gastroenterology. 2005; 39:230-242
2. Bockus HL, Bank J, Wilkinson SA. Neurogenic mucous colitis. American Journal of
Medical Science. 1928;176:813-823
3. Talley NJ, Zinsmeister AR, Van Dyke C, et al. Epidemiology of colonic symptoms
and the irritable bowel syndrome. Gastroenterology. 1991;101:927-934.
4. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional
gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis
Sci. 1993;38:1569-1580.
5. Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning
criteria for case identification in epidemiological investigations of irritable bowel
syndrome. American Journal of Gastroenterology. 2000;95:2816-2824.
6. Schuster MM. Defining and diagnosing irritable bowel syndrome. Am J Manag
Careh. 2001;7(suppl):246-251.
7. National Ambulatory Medical Care Survey. National Center for Health Statistics:
NAMCS Description. Available at:
8. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients
with functional gastrointestinal disorders. Gastroenterology. 1987;92:1282-1284.
9. Drossman DA, Corazziari E, Talley NJ, et al. Rome II. The Functional
Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A
Multinational Consensus, 2nd ed. McLean, VA: Degnon, 2000.
10. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a
five-year prospective study. Lancet. 1987;1:963-965.
11. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects
with irritable bowel syndrome. Gastroenterology. 1995;109:1736-1741.
12. American Gastroenterological Association. The Burden of Gastrointestinal Diseases.
Bethesda, MD: American Gastroenterological Association, 2001.
13. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestives
diseases in the United States. Gastroenterology. 2002;122:1500-1511.
14. Vanner SJ, Depew WT, Paterson MD, DaCosta LR, Groll AG, Simon JB, Djurfeldt
M. Predictive vale of Rome Criteria for diagnosing the irritable bowel syndrome.
The American Journal of Gastroenterology. 1999; 94. 2912-2916
15. Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Hertig V, Bond EF. Symptoms
across the menstrual cycle in women with irritable bowel syndrome. Am J
Gastroenterology. 2003;98: 420-430

8

16. Ruigomez A, Rodriguez LA, Johansson S, Wallander MA. Is hormone replacement
therapy associated with an increased risk of irritable bowel syndrome? Maturitas.
2003;44: 133-140
17. Houghton LA, Jackson NA, Whorwhell PJ, Morris J. Do male sex hormones protect
from irritable bowel syndrome? Am J Gastroenterology. 2000; 95:2296-2300.
18. Miller V, Whitaker K, Morris JA, Julie A, Whorwell PJ. Gender and irritable bowel
syndrome: the male connection. Journal Clinical Gastroenterology. 2004; 38:558-560
19. Ali A, Richardson D, Toner B. Feminine gender role and illness behaviour in
irritable bowel syndrome. Journal of Gender Culture Health. 1998;3:59-65
20. Drossman DA, Camilelleri M, Mayer EA, Whitehead WE. AGA technical review on
Irritable Bowel Syndrome. Gastroenterology 2002;123:2108-2131
21. Chami TN, Schuster MM, Bohlman NE, Pulliam TJ, Kamal N, Whitehead WE. A
simple radiological method to estimate the quantity of bowel gas. American Journal
of Gastroenterology. 1991;86:599-602.
22. King TS, Ekua M, Hunter JO. Abnormal colonic fermentation in irritable bowel
syndrome. Lancet. 1998;352:1187-1189
23. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding
irritable bowel syndrome. JAMA. 2004 852-858
24. Nucera C. Lupascu AM, Gabriella M, et al. Sugar intolerance in irritable bowel
syndrome: the role of small bacterial overgrowth. Gastroenterology. 2004;126(4): A511
25. Pimental M, Chow E, Lin HC. Eradication of small intestine bacterial overgrowth
reduces symptoms in irritable bowel syndrome. American Journal of
Gastroenterology. 2000. 3503-3506.
26. Pimental M, Chow E, Lin HC. Normalization of lactulose breath testing correlates
with symptom improvement in irritable bowel syndrome: a double blind
randomized controlled study. Gastroenterology 2003;98 412-419.
27. Nayak A, Karnad D, Abraham M, Mistry FP. Metronidazole relieve symptoms in
irritable bowel syndrome: the role of small bacterial overgrowth: the confusion with
so called “chronic amebiasis.” Indian Journal of Gastroenterology. 1997; 16: 137-139.
28. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after
bacterial gastroenteritis: cohort study. BMJ 1999; 318:565-566
29. Parry SD, Stansfield R, Jelly D, Gregory W, Phillips E, Barton JR, Welfare MR .
Does bacterial gastroenteritis predispose people to functional gastrointestinal
disorders? A prospective, community-based case-control study. American Journal of
Gastroenterology 2003; 98 1970-1975.
30. Parry S, Forgacs I. Intestinal infection and irritable bowel syndrome. European
Journal of Gastroenterology and Hepatology. 2005; 17: 5-9
31. Neal R, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a
six year follow-up study. Gut. 2002;51:410-413
32. Hiatt RB, Katz L. Mast cells in inflammatory conditions of the gastrointestinal
tract. Am J Gastroenterol 1962;37:541–545.
33. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ilealmucosal mast cells in
irritable bowel syndrome. Dig Dis Sci 1993;38:1590–1595.
34. O’Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A,
O’Morain CA. Increased mast cells in the irritable bowel syndrome.
Neurogastroenterol Motil 2000;12:449–457.
35. Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP. Methods in laboratory
investigation: morphometric study of colonic biopsies: a new method of estimating
inflammatory diseases. Lab Invest 1990;60:847–851.
36. Tornblom H, Lindberg G, Nyberg B, Veress B, Inst K. Histopathological findings in
the jejunum of patients with severe irritable bowel syndrome (abstr).
Gastroenterology 2000;118:A140.
37. O’Sullivan MA, Clayton N, Wong T, Bountra C, Buckley MM, O’Morain CA.
Increased inos and nitrotyrosine expression in irritable bowel syndrome (IBS)
(abstr). Gastroenterology 2000;118:A702.
38. Spiller RC. Inflammation as a basis for functional GI disorders. Best Practice and
Research Clinical Gastroenterology. 2004;18:641-661.
39. Tornblom H, Lindberg G, Nyberg B, Veress B. Full thickness biopsy of the jejunum
reveals inflammation and enteric neuropathy in irritable bowel syndrome.
Gastroenterology 2000; 123: 1972-1979.
40. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the
irritable colon syndrome. Gut 1973;14:125-132

Research & Review Articles

41. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the
irritable bowel syndrome. Journal of Clinical Gastroenterology. 2005; 39: S184-S193
42. Branchek T, Mawe G, Gershon MD. Characterization and localization of a
peripheral neural 5-hydroxytryptamine receptor subtype with a selective agonist, H5-hydroxyindalpine. J Neuroscience. 1088; 8:2582-2595
43. Craig DA, Clarke DE. Pharmacological characterization of a neuronal receptor for
5-hydroxytryptamine in guinea pig ileum with properties similar to 5-hydroxytryptamine4 receptor. Journal of Pharmacol Exp Ther. 1990; 252:1378-1386.
44. Galligan JJ, Pan H, Messori E. Signaling mechanism coupled to 5-hydroxytryptamine4 receptor mediated facilitation of fast synaptic transmission in the
guinea pig ileum myenteric plexus. Neurogastroenterol Motil. 2003;15:523-529.
45. Pan H, Galligan JJ. 5-HT1A and 5-HT4 receptor mediated inhibition and
facilitation of of fast synaptic transmission in enteric neurons. American Journal of
Physiology. 1994;266:G230-G238.
46. Mangle AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment
Pharmacol Ther. 1999;13(suppl2):77-82

referred to secondary care. Lancet 2001; 538: 1504-08
50. Locke GR, Murray JA, Zinsmeister AR, Melton LJ III, Talley NJ. Celiac disease
serology in irritable bowel syndrome and dyspepsia: A population-based case-control
study. Mayo Clinic Proceedings 2004; 79: 476-482
51. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle
relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther.
1994;8:499-510.
52. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo
in management of irritable bowel syndrome. Dig Dis Sci. 1984;29:239-247.
53. Tack J, Muller-Lissner, Bytzer P, et al. A randomised controlled trial assessing the
efficacy and safety of repeated tegaserod therapy in women with irritable bowel
syndrome with constipation. Gut 2005; 54(12): 1707-1713
54. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment
of functional gastrointestinal disorders with antidepressant medications: a metaanalysis. Am J Med. 2000;108:65-72.
55. Hameroff SR, Weiss JL, Lerman JC, et al. Doxepin's effect on chronic pain and
depression: a controlled study. J Clin Psychiatry. 1984;45(pt 2):47-53.

47. Humphrey PP, Bountra C, Clayton N, Kozlowski K. Review article: the therapeutic
potential of 5-HT3 receptor antagonist in the treatment of irritable bowel
syndrome. Aliment Pharmacol Ther. 1999;13 (suppl 2):31-38

56. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel
syndrome. A large-scale audit of a clinical service with examination of factors
influencing responsiveness. Am J Gastroenterol. 2002;97:955-961

48. Coremans G, Clouse RG, Carter F, et al. Cilansetron, a novel 5-HT3 antagonist,
demonstrated efficacy in males with irritable bowel syndrome with diarrhea
predominance (IBS-D). Gastroenterology 2004; 126 (suppl 2):105454

57. Bhuket T, Chey W. Hypnotherapy for irritable bowel syndrome: effectively
expanding the arsenal? Evidenced-Based Gastroenterology 2004;5(2)54-55

49. Sanders DS, Carter MJ, Hurlstone DP. Association of adult coeliac disease with
irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria

Forgotten Perspectives
Drawing courtesy of
Shruti Tewari, MD

9

